

Journal of Pharmaceutical Research International

33(39A): 102-106, 2021; Article no.JPRI.71003 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759)

Comparative Study of Serum Cystatin C and Serum Creatinine Level in Before and After Hemodialysis

Dattu Hawale¹, Ranjit Ambad^{2*}, Nandkishor Bankar³ and Raunak Kotecha⁴

¹Department of Biochemistry Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences Sawangi (Meghe) Wardha-442001, India. ²Department of Biochemistry Datta Meghe Medical College. Shalinitai Meghe Hospital and Research

Centre (Datta Meghe Institute of Medical Sciences), India. ³Department of Microbiology Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical

⁴Department of Microbiology Jawanarial Nenru Medical College, Datta Megne Institute of Medical Sciences, Sawangi (Meghe), Wardha , India.

⁴Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre (Datta Meghe Institute of Medical Sciences), India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i39A32147 <u>Editor(s):</u> (1) Dr. Mohamed Fawzy Ramadan Hassanien, Zagazig University, Egypt. <u>Reviewers:</u> (1) Amrita Roy, West Bengal University of Health Sciences, India. (2) Swapna Mary A, Rajiv Gandhi University of Health Sciences, India. Complete Peer review History: <u>https://www.sdiarticle4.com/review-history/71003</u>

Original Research Article

Received 22 May 2021 Accepted 28 July 2021 Published 29 July 2021

ABSTRACT

Background: Chronic kidney disease (CKD) is a pathophysiologic process characterised by a decrease in nephron number and function, which often leads to end-stage renal disease (ESRD). Serum plasma cystatin C is a new test for determining kidney function. Its accuracy in determining the efficacy of haemodialysis in patients with end-stage renal disease has yet to be determined. Serum cystatin C, which is formed at a constant rate by all nucleated cells and filtered freely by the glomerulus, is neither secreted nor reabsorbed, and is unaffected by non-renal influences. **Materials and Methods:** This study was a comparative study, conducted in the nephrology Department at DMMC & SMHRC, Nagpur in collaboration with ABVRH and JNMC Wardha, Sawangi (Meghe) during September 2020 to March 2021. Total 25 patient (End stage renal disease) included for the present study, the age group 30-60 years with 17 male patients and 08 female patients.

Result: Serum creatinine concentration in the before hemodialysis with 8.72 ± 3.00 and for the after hemodialysis $3.20\pm1.18(P < 0.0001)$. The serum cystatin C concentration in the before hemodialysis 5.50 ± 2.09 and for the after hemodialysis $8.7\pm1.75(P < 0.0001)$. the process of hemodialysis leads to a significantly low in a serum creatinine concentration as compared to before hemodialysis. The serum cystatin C concentration significantly increase in the after hemodialysis patient as compared to before hemodialysis.

Conclusion: Hemodialysis adequacy cannot be determined using serum cystatin C. It does, however, serve as a surrogate marker of dialysis inadequacy, particularly when low flux membranes are used. Routine examination of serum cystatin C in hemodialysis patients will help in the monitoring of the patient's overall clinical condition.

Keywords: Creatinine; cystatin C; Hemodialysis; ESRD.

1. INTRODUCTION

CKD is a growing health concern around the world. There has been a rise in the number of people affected by CKD as the incidence of conditions such as diabetes mellitus and hypertension among the global population has increased. The morbidity and mortality associated with CKD are a major concern. The majority of patients are diagnosed during endstage renal disease (ESRD) and, as a result of delayed intervention, frequently succumb to complications even after starting dialysis [1].

The effectiveness of dialysis has a significant impact on the health, outcome, and survival of patients with end-stage renal disease. As a result, careful monitoring and follow-up are needed to produce the best results. The effectiveness of dialysis is currently measured by measuring serum creatinine levels before and after each dialysis session. However, interindividual variability in serum creatinine levels is affected by age and gender [2].

Serum creatinine is primarily a metabolite of creatine, almost all of which is located in skeletal muscle. serum creatinine normal range in male 0.8-1.4 mg/dl and female 0.6-1.2 mg /dl .females creatinine have a lower as compared to males, because female muscle mass less as compared to males [3].

The sum of creatine per unit of skeletal muscle mass and the rate of creatine breakdown are also consistent. As a result, plasma creatinine concentration is very consistent and serves as a clear indicator of skeletal muscle mass [4]. In addition, body structure and dietary influences have an effect on plasma creatinine levels. e.g Consumption of meat, can increase plasma creatinine levels because it contains creatine, which can be converted to creatinine during cooking [5]. Cystatin C is a single non-glycosylated polypeptide chain with a molecular mass of 13 kDa and 120 amino acid residues [6].

Cystatin C is a small protein that is found in all nucleated cells, is generated at a constant rate, and is freely filtered by the glomerulus. It is not secreted, but rather reabsorbed and catabolized by tubular epithelial cells, preventing it from returning to the bloodstream. These characteristics make it a useful endogenous renal function marker [7].

The present study was therefore undertaken in order to evaluate the potential clinical utility of serum cystatin C determination in patients before and after hemodialysis.

2. MATERIALS AND METHODS

This study was a comparative study, conducted in the Biochemistry Department at DMMC & SMHRC, Nagpur in collaboration with ABVRH and JNMC Wardha, Sawangi (Meghe) during September 2020 to March 2021. Total 25 patient (End stage renal disease) included for the present study, the age group 30-60 years with 17 male patients and 08 female patients.

2.1 Inclusion Criteria

• End stage renal disease (ESRD)

2.2 Exclusion Criteria

- Heart disorders
- Thyroid disorders
- Illnesses
- Malignancies
- Chronic liver diseases
- Serology positive
- Patient on glucocorticoid therapy and pregnant women were excluded from this study.

2.3 Sample Collection

5 ml Blood sample was collected before and after hemodialysis from each patient by venipuncture with standard blood collection technique in a plain vial for serum separation for the estimation of serum cystatin C and serum creatinine.

2.4 Biochemical Analysis

- Serum creatinine concentration was estimated by Jaff's method.
- Serum Cystatin C concentration was estimated by turbidimetric immunoassay.

2.5 Statistical Analysis

The data were analyzed using SPSS software program, version 20.0. The mean and standard deviation were measured. Analyzed and interpreted using descriptive and inferential statistics. The probability value is less than 0.05 (p < 0.05) and it was considered as statistically significant.

3. RESULT

Table 1 show the serum creatinine concentration in the before hemodialysis with 8.72 ± 3.00 and for the after hemodialysis 3.20 ± 1.18 (P < 0.0001). The serum cystatin C concentration in the before hemodialysis 5.50 ± 2.09 and for the after hemodialysis 8.7 ± 1.75 . (P < 0.0001). The result show Table 1 Hemodialysis causes a substantial decrease in serum creatinine levels as compared to before hemodialysis (P< 0.0001). The serum cystatin C levels in the post-hemodialysis patient were significantly higher than in the prehemodialysis patient (P < 0.0001).

4. DISCUSSION

CKD is a multi-etiological pathophysiologic process that results in a decrease in nephron number which function, and often leads to endstage renal disease (ESRD). The glomerular filter normally clears molecules with molecular weights up to 58,000 Dalton (Da), but these solutes are stored in renal failure (ESRD). These retention products are usually divided according to their molecular weight and physiological properties [8-9].

Human cystatin C is primarily catabolized by free filtration in the glomeruli, induced by tubular reabsorption. The plasma renal clearance of cystatin C is 94 percent that of the commonly used glomerular filtration rate (GFR) marker. according to direct studies [10]. Present study Serum creatinine concentration was significantly increased in the before hemodialysis patient and after hemodialysis serum creatinine levels was significantly decreased in compared to the before hemodialysis patient (P < 0.0001). N Krishnamurthy, et al. [11] Pre-dialysis serum creatinine concentration ranged from 4.49 to 12.24 mg/dL, with a mean and SD of 7.72 \pm 2.22 mg/dL, and post-dialysis serum creatinine levels levels ranged from 1.64 to 5.73 mg/dL, with a mean and SD of 2.90 ±1.11 mg/dL. The finding showed posthemodialysis a significant decrease in mean serum creatinine concentration. Tridip Kutum et al. [12] also show the pre-dialysis group had significantly higher serum creatinine concentration than the control group (p<0.0001). With p<0.0001, the postdialysis serum creatinine concentration was significantly lower than the pre-dialysis group. Creatinine is almost entirely formed in the muscle, creatinine excretion is affected by muscle mass; thus, urinary excretion is the most accurate index to identify muscle mass [12-13]. Our Present study the serum cystatin C concentration were significantly increase in the after hemodialysis patient as compared to before hemodialysis (P < 0.0001). Lindstrom et al. [14] also observed that low flux hemodialysis did not reduce cystatin C. Their study also showed decrease in cvstatin С levels with Hemodiafiltration and hemofiltration (to 28% and 44% respectively) (p<0.001) They found that

 Table 1. Serum creatinine concentration and serum cystatin C concentration in before and after hemodialysis

	Before Hemodialysis	After Hemodialysis	P value
Serum creatinine concentration (mg/dl)	8.72±3.00	3.20±1.18	P < 0.0001
Serum cystatin C	5.50±2.09	8.7±1.75	
concentration (mg/dl)			P < 0.0001

cystatin C rebound post hemodialysis leading to a rise in cystatin C level by 12% in hemodiafiltration group. The nature of the dialyzing membrane and the composition of the dialyzing fluid could both contribute to the increase in serum cystatin C concentration after dialysis [15].

When dialysis is done with a low flux membrane, the pore size is less than 1.5 nm, making it impossible to remove low molecular weight proteins like cystatin C. The electrostatic interaction between micro-proteins and other plasma proteins adsorbed onto the dialyzer membranes is another factor to consider. Cystatin C is a strongly cationic molecule, and its charged nature can make it difficult to filter [16]. The effect of hemoconcentration, which occurs during dialysis, may also be to increase in serum cystatin C concentration. Despite these shifts, serum creatinine decreases due to the extent of this metabolite's reduction during dialysis [17-22].

5. CONCLUSION

Hemodialysis adequacy cannot be determined using serum cystatin C. It does, however, serve as a surrogate marker of dialysis inadequacy, particularly when low flux membranes are used. Routine examination of serum cystatin C in hemodialysis patients will help in the monitoring of the patient's over all clinical condition.

ETHICAL APPROVAL

Ethical clearance taken from institutional ethics committee

CONSENT

As per international standard or university standard, patient's written consent has been collected and preserved by the author(s).

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137(6):479-86.
- James GD, Sealey JE, Alderman M, Ljungman S, Mueller FB, Pecker MS, Laragh JH. A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens. 1988;1:124-31.
- Molitoris BA. Acute kidney injury. In Goldman L, Ausiello D, editors. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007. p. chap 121.
- 4. Buran, T., Sanem Gökçe Merve Kılınç, & Prevalence Elmas Kasap. of Extraintestinal Manifestations of Ulcerative Colitis Patients in Turkey: Community-Based Monocentric Observational Study. Clinical Medicine and Medical Research. 2020;1(2):39-46. Available:https://doi.org/10.52845/CMMR/2 020v1i2a8
- Martin RF. Renal Function. In Clin Chem Theory, Analysis, Correlation. 4th ed. St. Louis, Missouri, Mosby. Philadelphia, Pa: Saunders Elsevier. 2003;483–484.
- Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis. 1998;32:S5-13.
- Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312–8.
- Daniel V, Daniel K. Diabetic neuropathy: new perspectives on early diagnosis and treatments. Journal of Current Diabetes Reports. 2020;1(1):12–14. Available:https://doi.org/10.52845/JCDR/2 020v1i1a3
- 9. lateraza of price CP, Scott MG. Cystatin Can improved estimate of glomerular filtration rate .clin chem. 2002;(5)48:699-707.

- 10. Vanholder R. Uremic toxins. Nephrol. 1997;26:143-163.
- 11. Vanholder R, De Smet R, et al. Review on uremic toxins: Classification, concentration, and inter-individual variability Kidney Int. 2003;63:1934-1943.
- 12. Tridip Kutum et al. A Study of Serum Cystatin C in Chronic Kidney Disease Patients Undergoing Hemodialysis. JMSCR. 2016(8):13187-13195.
- Daniel V, Daniel K. Perception of Nurses' Work in Psychiatric Clinic. Clinical Medicine Insights. 2020;1(1):27-33. Available:https://doi.org/10.52845/CMI/20 20v1i1a5
- Krishnamurthy N, et al. Effect of hemodialysis on circulating cystatin c levels in patients with end stage renal disease. Indian Journal of Clinical Biochemistry. 2010;25(1):43-46.
- 15. Agraharkar M, Nair V, Patlovany M. Recovery of renal function in dialysis patients. BMC Nephrol. 2013;4(9):1-5.
- Heymsfield SB, Stevens V, Noel R, ct al. Biochemical composition of muscle in normal and protein energy starved human subjects: relevance to anthropometric measurements. Am J Clin Nutr. 1982;36: 131-42.
- 17. Lindstrom V, Grubb A, Alquist HM, Christensson A. Different elimination patterns of beta trace protein, beta2 microglobulin and cystatin C in hemodialysis, hemodiafiltration and

hemofiltration. Scan J clin Invest. 2008; 68(8):685-691

 Daniel V, Daniel K. Exercises training program: It's Effect on Muscle strength and Activity of daily living among elderly people. Nursing and Midwifery. 2020;1(01): 19-23.

Available:https://doi.org/10.52845/NM/202 0v1i1a5

- Ambad R, et al. Relationship between uric acid and creatinine in pre-diabetic and diabetic patients: Vidarbha region of Maharashtra. Int. J. Res. Pharm. Sci. 2020;11(3):3412-3417.
- Kabanda A, Jadoul M, Pochet JM, Lauwerys R, Strihou CAY, Bernard A, et al. Determinations of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int. 1994;45:1689-96.
- Shilpak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Breen CS, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–45.
- Sakshi Minocha, Srishti Kumari, Akhilesh Tiwari, Anil Kumar Gupta, Sanyam Gandhi, Ajay Sharma, An Overview On Tannins, International Journal of Pharmaceutical and Biological Science Archive. 2015;3(2):09-11. ISSN: 2349-2678

© 2021 Hawale et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: https://www.sdiarticle4.com/review-history/71003